BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2808 related articles for article (PubMed ID: 19005398)

  • 1. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD; Nezakatgoo N; Lorber MI; Nashan B; Tedesco-Silva H; Kasiske BL; de la Cruz FJ; Russ G; Campistol J; Keown PA;
    Transplantation; 2009 Oct; 88(8):1010-8. PubMed ID: 19855247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
    Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
    Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
    Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
    van Hooff JP; Squifflet JP; Wlodarczyk Z; Vanrenterghem Y; Paczek L
    Transplantation; 2003 Jun; 75(12):1934-9. PubMed ID: 12829890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR; Jensik S; Pescovitz M; Pirsch J; Adler SH; Thistlethwaite JR; Vincenti F; Cohen DJ
    Clin Transplant; 2005 Feb; 19(1):130-6. PubMed ID: 15659146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
    Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.
    Trompeter R; Filler G; Webb NJ; Watson AR; Milford DV; Tyden G; Grenda R; Janda J; Hughes D; Ehrich JH; Klare B; Zacchello G; Bjorn Brekke I; McGraw M; Perner F; Ghio L; Balzar E; Friman S; Gusmano R; Stolpe J
    Pediatr Nephrol; 2002 Mar; 17(3):141-9. PubMed ID: 11956848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
    Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
    Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 141.